In re Pharmaceutical Industry Average Wholesale Price Litigation

509 F. Supp. 2d 82
District Court, D. Massachusetts·Decided September 17, 2007·No. MDL No. 1456; Civil Action No. 01-12257-PBS·Published·Cited by 11 cases

Opinion

[88]*88 MEMORANDUM AND ORDER

SARIS, District Judge.

I. INTRODUCTION

In these cases, Attorneys General from the states of Illinois, Ohio, Florida, Mississippi, Kentucky, Idaho, Pennsylvania and the New York Counties of Oswego, Erie and Schenectady allege that pharmaceutical companies fraudulently inflated drug prices which caused the states and counties to pay excessive reimbursements under the Medicaid program. Each complaint, alleging state causes of action, was filed in state court. Defendant Dey, Boeh-ringer, or Abbott has removed each of these cases, arguing that the unsealing of the federal False Claims Act actions against them provides a new basis for federal jurisdiction. Plaintiffs, arguing that removal is groundless and untimely, seek remand. After hearing, the motions to remand all the actions are ALLOWED.

II. BACKGROUND

Plaintiffs’ claims form part of the massive Average Wholesale Price (“AWP”) multidistrict litigation (“MDL”) pending in this Court. The Court assumes close familiarity with that lawsuit, as well as the alleged drug pricing schemes discussed in its previous AWP MDL decisions. See, e.g., In re Pharm. Indus. Average Wholesale Price Litig., 491 F.Supp.2d 20 (D.Mass. June 21, 2007); (making findings of fact and conclusions of law following a bench trial on claims under Massachusetts consumer protection laws); In re Pharm. Indus. Average Wholesale Price Litig. 431 F.Supp.2d 98 (D.Mass.2006) (remanding cases); In re Pharm. Indus. Average Wholesale Price Litig., 230 F.R.D. 61 (D.Mass.2005) (certifying a national class action); In re Pharm. Indus. Average Wholesale Price Litig., 263 F.Supp.2d 172 (D.Mass.2003) (dismissing RICO claims).

The United States has also been active in bringing AWP litigation against the same pharmaceutical manufacturers, in the form of qui tarn lawsuits pursuant to the federal False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq. On March 17, 2006, the United States intervened in a qui tam lawsuit against various pharmaceutical defendants, United States ex rel. Ven-a-Care of the Florida Keys, Inc., et al. v. Abbott Laboratories, Civil Action No. 95-1354-CIV (S.D.Fla.);1 United States of America ex rel. Ven-A-Care of the Florida Keys, Inc. v. Dey, Inc., et. al., Civil Action No. 05-11084-MEL (D.Mass.);2 United States of America ex rel. Ven-A-Care of the Florida Keys, Inc., et al. v. Boehringer Ingelheim Corporation, et al., Civil Action No. 07-10248-MEL (D.Mass.). These federal actions concern the same factual circumstances and fraud allegations as the state actions. The defendants subsequently removed the cases that were pending in state courts arguing that 31 U.S.C. § 3732(b)3 confers original federal jurisdiction given the existence of the federal false claims action.4 All actions were [89]*89subsequently transferred to this Court as part of this multidistrict litigation. The plaintiff states and New York counties have moved to remand the cases back to the state courts.

Defendants in the Illinois and Ohio actions moved for leave to file an additional ground for removal. On October 24, 2006 this Court issued a decision, as part of this MDL, denying the state of Arizona’s motion to remand its case. See In re Pharm. Indus. Average Wholesale Price Litig., 431 F.Supp.2d 77 (D.Mass.2006) (Saris, J.). In that order, I explained that the claims on behalf of Medicare Part B beneficiaries raised a substantial federal issue such that federal jurisdiction was appropriate under the test formulated by the Supreme Court in Grable & Sons Metal Products, Inc. v. Darue Engineering & Manufacturing, 545 U.S. 308, 125 S.Ct. 2363, 162 L.Ed.2d 257 (2005). Defendants now assert that in the Illinois and Ohio cases, removal is proper because the complaints seek recovery of Medicare Part B prescription drug co-payments and the removal notices were filed within thirty days of the Arizona decision.

III. DISCUSSION

A. Removal Based on the Unsealing of the Qui Tam Actions

Defendants removed the cases pursuant to 28 U.S.C. § 1441, which states that “any civil action brought in a state court of which the district courts of the United States have original jurisdiction, may be removed — ”28 U.S.C. § 1441(a). Original federal question jurisdiction exists over “civil actions arising under the Constitution, laws, or treaties of the United States.” 28 U.S.C. § 1331. The defendant bears the burden of establishing the existence of federal jurisdiction. BIW Deceived v. Local S6, 132 F.3d 824, 831 (1st Cir.1997). The removal statute should be strictly construed, and any doubts about the propriety of removal should be construed against the party seeking removal. See, e.g., Danca v. Private Health Care Sys., Inc., 185 F.3d 1, 4 (1st Cir.1999).

Defendants contend that 31 U.S.C. § 3732(b) constitutes a basis for original subject matter jurisdiction, making the cases removable. Under § 3732(b), “[t]he district courts shall have jurisdiction over any action brought under the laws of any State for the recovery of funds paid by a State or local government if the action arises from the same transaction or occurrence as an action brought under section 3730.” Section 3730 provides for civil actions under the federal False Claims Act. Because the federal and state cases against Dey arise from the same transaction or occurrence, defendants argue that federal courts have jurisdiction over both cases.

1. Timeliness of Removal

The threshold issue is the timeliness of the removal. Generally, a defendant must seek removal within thirty days of receipt of the pleadings or summons. 28 U.S.C. § 1446(b). However, a defendant may also file a notice of removal “within thirty days after receipt by the defendant, through service or otherwise, of a copy of an amended pleading, motion, order or other paper from which it may first be ascertained that the case is one which is or has become removable.” Id. It is undisputed that defendants did not file a removal notice within thirty days of the initial pleading.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Pharmaceutical Industry Average Wholesale Price Litigation, 509 F. Supp. 2d 82 (D. Mass. 2007).

509 F. Supp. 2d 82 (In re Pharmaceutical Industry Average Wholesale Price Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

USA ex rel Mohajer
S.D. New York, 2021
Dias v. Genesco, Inc.
D. Massachusetts, 2019
Dias v. Genesco, Inc.
365 F. Supp. 3d 158 (District of Columbia, 2019)
Waithaka v. Amazon.com, Inc.
D. Massachusetts, 2018
Frederick v. Service Experts Heating & Air Conditioning LLC
114 F. Supp. 3d 1175 (N.D. Alabama, 2015)
Merchants Automotive v. Advantage Opco
2014 DNH 241 (D. New Hampshire, 2014)
United States v. Deming Hospital Corp.
992 F. Supp. 2d 1137 (D. New Mexico, 2013)
Haber v. Massey
904 F. Supp. 2d 136 (D. Massachusetts, 2012)
Estate of Combas Martinez v. Barros & Carrion
668 F. Supp. 2d 334 (D. Puerto Rico, 2009)
Wisconsin v. Amgen, Inc.
516 F.3d 530 (Seventh Circuit, 2008)
In Re Pharmaceutical Ind. Aver. Wholesale Price
509 F. Supp. 2d 82 (D. Massachusetts, 2007)